Mesenchymal Stem Cells Treat Liver Cirrhosis

• Status: Suspended
• Trial end date: 2019-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to investigate the efficacy of umbilical cord mesenchymal stem cells (MSCs) transfusion in the treatment of liver cirrhosis. Liver function will be monitored by serum analysis. The levels of serum alanine aminotransferase (ALT), total bilirubin (TB), prothrombin time (PT), prealbumin(PA) and albumin (ALB) will be examined at pre-transfusion, and 3 days to 2 years post-transfusion. Child-Pugh scores, Model for End-Stage Liver Disease scores and clinical symptoms will be assessed simultaneously.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Yufang Shi
• Collaborator: Soochow University

Criteria

Inclusion Criteria:

• Age 18-70 years.

• Imaging evidences of liver cirrhosis.

• Child-Plough score of 8 or more.

• Model for End-Stage Liver Disease score of 20 or more.

Exclusion Criteria:

• Liver tumor on ultrasonography, CT or MRI examination.

• Problems in organs other than liver (e.g. heart or lungs).

• History of moderate to severe hepatic encephalopathy or variceal bleeding.

• Imaging evidences of vascular thromboses.

• Coma.